Sandostatin LAR 20 mg ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
227Osler disease1

227. Osler disease


Clinical trials : 54 Drugs : 73 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2016-001340-19-NL
(EUCTR)
21/07/201611/07/2016The effectiveness of the drug octreotide LAR to anemia in patients with gastrointestinal bleeding due to Rendu-Osler-Weber disease.An uncontrolled, pilot-study assessing the efficacy of octreotide LAR to decrease transfusion requirements and endoscopy frequency in patients with Rendu-Osler-Weber and gastrointestinal bleeding - ROW Patients with Rendu-Osler-Weber disease (which is also called: Hereditary hemorrhagic telangiectasia);Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Trade Name: Sandostatin LAR 20 mg
Product Name: Sandostatin LAR
Product Code: RVG 18236
Radboud University Medical CenterNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Phase 2Netherlands